Choline Composition for Dry Eye Autonomic Dysfunction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for treating autonomic dysfunction and its associated conditions, such as dry eyes and vascular disorders, often focus on symptom relief rather than addressing the root causes, and may come with adverse side effects, while existing treatments for dry eyes are inadequate in addressing neurological causes.
Innovation Solution
A composition comprising a choline compound, a cholinesterase inhibitor, and Acetyl-L-Carnitine is administered to treat dry eye and autonomic dysfunction, improving tear break-up time, corneal staining, and Ocular Surface Disease Index, and is designed to stimulate post-ganglionic nicotinic acetylcholine receptors to correct underlying organ dysfunction.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current methods for treating autonomic dysfunction are used, then symptom relief is achieved, but the root causes are not addressed and adverse side effects occur
Solution Approach 1:
The patent applies preliminary action by administering a composition containing choline compound, cholinesterase inhibitor, and Acetyl-L-Carnitine before autonomic dysfunction symptoms fully develop or worsen. This composition restores acetylcholine levels and stimulates post-ganglionic nicotinic receptors proactively, preventing the progression of dry eyes and other autonomic dysfunction symptoms rather than merely responding to established symptoms.
Solution Approach 2:
The patent uses acetylcholine as an intermediary substance to mediate communication between the nervous system and target organs. By administering choline compounds and cholinesterase inhibitors, the patent increases acetylcholine availability, which then acts as a mediator to stimulate post-ganglionic nicotinic receptors and restore proper organ function, addressing root causes rather than just symptoms.
2Ease of operation
If existing treatments for dry eyes are used, then some symptom relief is provided, but neurological causes are not addressed
Solution Approach 1:
The patent applies preliminary action by addressing the neurological cause of dry eyes through acetylcholine restoration before ocular symptoms become severe. The composition of choline compound, cholinesterase inhibitor, and Acetyl-L-Carnitine works proactively to stimulate lacrimal gland function via post-ganglionic nicotinic receptor activation, preventing tear deficiency rather than merely treating established dry eye symptoms.
Solution Approach 2:
The patent uses acetylcholine as an intermediary to bridge the neurological cause and ocular manifestation of dry eyes. By increasing acetylcholine levels through choline supplementation and cholinesterase inhibition, the patent enables proper neural signaling to the lacrimal gland, addressing the root neurological dysfunction that existing treatments fail to address.
3Loss of time
If symptom-focused treatments are used, then immediate relief may be achieved, but underlying organ dysfunction persists
Solution Approach 1:
The patent merges symptom relief with root cause treatment by combining choline compound, cholinesterase inhibitor, and Acetyl-L-Carnitine into a single composition. This unified approach simultaneously restores acetylcholine levels (addressing neurological causes), stimulates post-ganglionic nicotinic receptors (correcting organ dysfunction), and provides symptomatic relief for dry eyes and other autonomic dysfunction manifestations, achieving both goals concurrently rather than sequentially.
Solution Approach 2:
The patent applies universality by creating a multi-functional composition that addresses multiple aspects of autonomic dysfunction simultaneously. The choline compound, cholinesterase inhibitor, and Acetyl-L-Carnitine work together to restore neurotransmitter levels, stimulate receptor function, and improve organ performance across multiple systems (ocular, cardiovascular, gastrointestinal), providing comprehensive treatment rather than isolated symptom management.
Data Source
AI summary
The present invention includes compositions and methods for treating certain conditions such as dry eye or dry mouth with a comprising a choline compound; a cholinesterase inhibitor; and Acetyl-L-Carnitine, wherein the composition is provided in an amount sufficient to treat dry eye or dry mouth.